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Context: Increased cortisol levels in obesitymay contribute to the associatedmetabolic syndrome. In
obesity, the activated innate immune system leads to increased interleukin (IL)-1b, which is known
to stimulate the release of adrenocorticotropin hormone (ACTH).
Objectives:Wehypothesized that in obesity IL-1 antagonismwould result in downregulation of the
hypothalamo-pituitary-adrenal axis, leading to decreased cortisol levels.
Design and Participants: In this prospective intervention study, we included 73 patients with obesity
(body mass index [BMI]$30 kg/m2) and at least one additional feature of the metabolic syndrome.
Outcome Measures: The primary end point was change in morning cortisol from baseline to after
the administration of the IL-1 receptor antagonist (anakinra/Kineret®, total dose 3 3 100 mg).
Secondary end points were effects on salivary cortisol and ACTH.
Results:Median age was 56 years, 50.7% of patients were female, and median BMI was 36.3 kg/m2.
Median morning serum cortisol levels (nmol/L) decreased significantly after IL-1 antagonism [from
baseline, 452 to 423; absolute difference,238.7; 95% confidence interval (CI),264 to213.4; P = 0.0019].
Similar effectswere found for salivary cortisol levels (22.8; 95%CI,24.4 to21.3; P= 0.0007), ACTH levels
(22.2; 95% CI;24.2 to20.1; P = 0.038), systolic blood pressure (25.2, 95% CI,28.5 to21.8; P = 0.0006),
and heart rate (22.9; 95% CI, 24.7 to 21.0; P = 0.0029).
Conclusion: IL-1 antagonism in obese individuals with features of themetabolic syndrome leads to a
decrease in serum cortisol, salivary cortisol, and ACTH levels along with a reduction in systolic blood
pressure and heart rate. (J Clin Endocrinol Metab 102: 1712–1718, 2017)
Obesity is a worldwide pandemic, associated with ahigh prevalence of comorbidities, leading to the
metabolic syndrome (1, 2). New treatment strategies are
warranted to prevent obesity-related comorbidities and
improve their treatment.
Data about cortisol levels in obesity are conflicting (3).
Whereas some studies have reported normal baseline cor-
tisol levels and higher urinary cortisol levels resulting from
an increased degradation upon an enhanced 11b-hydroxy-
steroid dehydrogenase type 1 activity (4), other studies
have reported increased baseline cortisol levels in patients
with central obesity resulting from an overactivated
hypothalamo-pituitary-adrenal (HPA) axis (3, 5, 6) and a
positive association of cortisol with visceral fat accu-
mulation (7). In patients with the metabolic syndrome,
cortisol levels were even higher, according to the amount
of the underlying metabolic features (8, 9). Elevated
cortisol levels as seen in Cushing syndrome are known to
be associatedwith ametabolic dysregulation and diabetes
eventually leading to cardiovascular mortality (10–12).
Obesity leads to a pathological activation of the innate
immune system characterized by changes in cytokines,
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chemokines, and the number and
activation state of various leukocyte
populations (13). As a result, in-
terleukin-1b (IL-1b) seems to play a
central role. Indeed, IL-1b pro-
duction is increased in several tissues,
including the hypothalamus (14–16).
After weight loss by lifestyle in-
terventions (17) or bariatric surgery (18, 19), IL-1b and
IL-1b–dependent inflammatory factors such as leuko-
cytes, C-reactive protein (CRP), and IL-6 decrease.
Clinical studies have shown that IL-1 antagonism may
improve insulin secretion or sensitivity and glycemia in
obese individuals as well as in patients with type 2 di-
abetes (20). However, it is unknownwhether these effects
are associated with changes in the activation of the
HPA axis.
Previous studies have evaluated the interaction be-
tween the immune and neuroendocrine systems, showing
that several cytokines have stimulatory effects on the
HPA axis (21). In particular, IL-1b appears to have a
strong stimulatory effect on adrenocorticotropin hor-
mone (ACTH) secretion in rodents (22–24). This was
explained by the colocalization of IL-1 and corticotropin-
releasing hormone producing cells in the hypothalamus
(25, 26) but also by a direct stimulatory effect of IL-1 on
the ACTH-producing cells at the level of the pituitary (23,
27, 28). Furthermore, a direct effect on cortisol pro-
duction in the adrenal glands was reported (27, 29).
Similarly, in lean, healthy humans, the intravenous or
subcutaneous administration of IL-1b led to elevated
plasma ACTH and cortisol levels (27, 30, 31).
Based on this information, we hypothesized that the
activation of the IL-1 system observed in some obese
individuals may stimulate the HPA axis and therefore
that IL-1 antagonism would decrease ACTH and cortisol
levels in these individuals.
Methods
Study design
This prospective, open-labeled, interventional study in-
volved 76 patients with obesity and at least one additional
feature of themetabolic syndrome. All patients were recruited at
the University Hospital Basel from October 2014 to January
2016 and received a total of five injections of a recombinant
human IL-1 receptor antagonist (100 mg of anakinra/Kineret®)
within 3 days. The consecutive injections were started at 8 PM
and continued in 12-hour intervals (Figure 1).
Patients
The study was conducted according to the ethical
guidelines of the Declaration of Helsinki and the applicable
International Conference on Harmonization guidelines on
good clinical practice. The local ethical committee approved
the study. Written informed consent was obtained from
all patients.
Inclusion criteria were age between 18 and 80 years, body
mass index (BMI) $30 kg/m2, and at least one of the following
additional features of the metabolic syndrome: hyperglyce-
mia (hemoglobin A1c $5.7%/39 mmol/mol), hypertension
(blood pressure $130/85mm Hg or treatment of hyperten-
sion), or dyslipidemia (high-density lipoprotein ,1.0 mmol/L
or triglycerides $1.7 mmol/L or low-density lipoprotein
.3.4 mmol/L or lipid-lowering treatment). Exclusion criteria
were medication with glucocorticoids, known Cushing
syndrome, chronic inflammatory disease, history of a severe
infection within the previous 2 months or an acute infection,
severe hematologic, kidney (creatinine clearance,30mL/min)
or liver disease (transaminases more than four times the upper
normal range), cancer, history of tuberculosis, chronic alcohol
abuse, pregnancy, or breastfeeding.
Study procedures
All patients attended a screening visit in which a study doctor
checked medical records and performed blood sampling and a
physical examination.
The study sequence consisted of four study visits taking place
within 2 weeks for each patient. All visits were scheduled be-
tween 7:30 AM and 10 AM after an overnight fast. To not
confound cortisol values by circadian rhythm, study visits for
every participant were consistently scheduled at the same time.
At each of these four visits, clinical parameters were assessed
and blood and salivary samples were taken.
At the first visit (baseline visit) a body impedance analysis
was performed. The following day, patients attended the second
study visit (dexa only) after a 1-mg dexamethasone suppression
test (intake of 1 mg dexamethasone Galepharm® orally at
midnight). Between visits two and three, there was a “washout”
period of 7 days.
After three injections of anakinra within 2 days, patients
attended the third study visit (anakinra only visit) and came the
following day for visit four (anakinra plus dexa, with two
additional injections of anakinra and intake of 1 mg dexa-
methasone Galepharm® at midnight). For the detailed study
schedule, see Fig. 1.
Laboratory values
Cortisol was measured with an electrochemiluminescence
immunoassay (CLIA; Elecsys cortisol test; Roche Diagnostics
GmbH,Mannheim, Germany) with an intra-assay coefficient
of variation of 1.0% to 1.7% and interassay coefficient of
variation of 1.4% to 2.8%. Salivary cortisol was collected
with Salivette® Cortisol (article number 51.1534.500;
Sarstedt AG & Co., Nu¨mbrecht, Germany). All laboratory
analyses were conducted at central laboratories at University
Hospital Basel.
Figure 1. Study schedule for all participating patients. The consecutive injections of anakinra
started on day 7 at 8 PM and continued with 12-hour intervals. The primary end point was
comparison of baseline cortisol to cortisol levels after three injections of anakinra. DST,
dexamethasone suppression test.
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IL-6 was measured with CLIA (Elecsys IL-6 test; Roche
Diagnostics GmbH) with a reference range,7 pg/mL. CRPwas
determined with an immunoturbidimetric assay (Tina-quant
C-Reactive Protein Gen. 3 Test; Roche Diagnostics GmbH).
ACTH was quantified with a CLIA (ACTH Immulite; Siemens
Health Care Diagnostics Products Ltd., Gwynedd, UK), with a
reference range,46.0 pg/mL. Prolactinwas determinedwith an
electro-CLIA (ECLIA) (Elecsys Prolactin II test; Roche Di-
agnostics GmbH), thyrotropin (TSH) was measured with an
ECLIA (Elecsys TSH test; Roche Diagnostics GmbH). Human
growth hormone was quantified with a CLIA (Immunlite 2000
hGH; Siemens Health Care Diagnostics Products Ltd.). Lutei-
nizing hormone (LH) and follicle-stimulating hormone (FSH)
were determined with an ECLIA (Elecsys LH and FSH Test;
Roche Diagnostics GmbH).
Study end points
The predefined primary end point was change in serum
morning cortisol levels from baseline to after three injections of
anakinra (visit 3). Predefined secondary end points were change in
salivary cortisol and ACTH from baseline to after anakinra,
changes of CRP and IL-6, and change in serum cortisol levels
between a 1-mg dexamethasone suppression test and 1-mg
dexamethasone suppression test plus additional administration of
anakinra. A further secondary end point was the prediction of
inflammatory markers (i.e., IL-6 and CRP) and body composition
measurements (e.g., BMI) on treatment response to anakinra.
Power calculation and statistical analysis
Our sample size calculation was based on the assumption that
morning cortisol levels would decline from 500 nmol/L (standard
deviation 6 90) to 450 nmol/L upon antagonizing IL-1 with
anakinra. Sixty-nine participants were needed to give this study a
power of 80% to showa significant difference inmorning cortisol
levels using a paired t test. Assuming a lost to follow-up rate of
10%, we aimed to include a total of 76 patients.
Discrete variables are expressed as counts (percentage) and
continuous variables asmedians and interquartile ranges (IQRs)
unless stated otherwise. For two-group comparison with paired
data, we used aWilcoxon test.We used linear regressionmodels
to estimate treatment response of anakinra on changes (D) in
serum cortisol, salivary cortisol, and ACTH levels before and
after treatment of different predefined predictors (i.e.,
median IL-6 levels, CRP levels, statin use,
BMI, waist circumference, age, sex, di-
abetes, hypertension, low-density lipo-
protein cholesterol).
Testing was two-tailed, and P , 0.05
was considered statistically significant.
For statistical analysis, we used GraphPad
Prism®, version 6.0, for Mac (GraphPad
Software, La Jolla, CA) and STATA 12.1
(Stata Corp, College Station, TX).
Results
Baseline characteristics
In total, 212 patients were pre-
screened. Of these, 136 did not fulfill
the eligibility criteria or denied par-
ticipation. Seventy-six patients were
included in the study, but three of these patients did not
complete the study: two patients withdrew informed
consent after the screening visit and one patient was
excluded before receiving the study medication because
he suffered an acute cardiac decompensation needing
hospitalization. Seventy-three patients received the study
medication and completed the trial (Fig. 2).
The median age of the 73 patients was 56 years (48 to
63), median BMI was 36.3 kg/m2 (33.3 to 40.9), 50.7%
were female, 64.4% of the patients had a type 2 diabetes
mellitus, 21.9% suffered from impaired glucose tolerance,
76.7% from hypertension, and 79.5% from dyslipidemia.
A complete description of the baseline characteristics is
given in Table 1.
Effects of IL-1 antagonism on the HPA axis
Morning serum cortisol levels decreased upon IL-1
antagonism frommedian (IQR) 452 nmol/L (374; 549) at
baseline to 423 nmol/L (337; 491) after three injections of
anakinra [absolute difference, 238.7; 95% confidence
interval (CI), 264 to 213.4; P , 0.01]. Salivary cortisol
levels decreased from 19.2 nmol/L (15; 25.5) to
15.5 nmol/L (11.9, 23.7) (absolute difference, 22.8;
95%CI,24.4 to21.3;P, 0.001), andACTH levels from
26.4 pg/mL (19.5; 32.9) to 23.7 pg/mL (19; 33.2) (absolute
difference, 22.2; 95% CI, 24.2 to 20.1; P = 0.038),
respectively. In contrast, there was no change in serum
cortisol levels after the 1-mg dexamethasone suppression
test and the dexamethasone suppression test plus IL-1
antagonism [28 nmol/L (19; 45) and 27.5 nmol/L (20;
45), P = 0.17] [Fig. 3(a–c)].
There was no change in other pituitary hormones (i.e.,
LH, FSH, TSH, growth hormone, and prolactin) upon
IL-1 antagonism. As expected, there was a decrease
of inflammatory parameters (leukocytes, neutrophile
granulocytes, CRP, and IL-6 upon IL-1 antagonism)
(Table 2).
Figure 2. Trial profile. Three of the 76 included patients dropped out before receiving the
study medication. All remaining 73 patients completed the trial and were analyzed for the
primary end point.
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Predictors of treatment response
We also investigated treatment response to IL-1 an-
tagonism in different subgroups [Supplemental Fig.
4(a–c)]. As a result, high baseline IL-6 was an important
predictor for a positive treatment response to IL-1 an-
tagonism. Compared with patients with IL-6 levels below
the median (i.e., 3.7 pg/mL), patients with baseline
IL-6 $3.7 pg/mL had a more pronounced decrease in
salivary cortisol (mean difference,23.40; 95%CI,26.49
to 20.31; P = 0.03) and in ACTH (mean difference,
23.87; 95% CI, 27.93 to 0.18; P = 0.06). In contrast,
CRP did not predict the IL-1 receptor antagonist treat-
ment response (data not shown). Patients on statin
therapy showed a poorer treatment response with regard
to delta salivary cortisol levels compared with patients
without statin treatment (mean difference, 3.02; 95%
CI, 20.01 to 6.13; P = 0.057).
A BMI lower than the median (i.e., 36.6 kg/m2) was
associated with a more pronounced effect on delta serum
cortisol levels (mean difference 48.0; 95% CI, 21.65
Table 1. Baseline Characteristics of All Patients
n = 73
Age, y 56 (48; 63)
BMI, kg/m2 36.3 (33.3; 40.9)
Weight, kg 106 (96; 123)
Female 37 (50.7%)
Caucasian 68 (93.2%)
Current smoker 13 (17.8%)
Diabetes mellitus type 2 47 (64.4%)
Impaired glucose tolerance 16 (21.9%)
Arterial hypertension 56 (76.7%)
Dyslipidemia 58 (79.5%)
Comorbidities
Obstructive sleep apnea 35 (47.9%)
Psychiatric diseases 18 (24.7%)
Known hypothyreoidism 11 (15.1%)
Known hypogonadism in men 2 (5.6%)
Medication
Oral anidiabetic drugs 39 (53.4%)
Insulin 25 (34.2%)
GLP-1 analogon 17 (23.3%)
Antihypertensive medication 53 (72.6%)
Statin 35 (47.9%)
NSAID 4 (5.5%)
Antidepressant drugs 11 (15.1%)
Antipsycotic drugs 1 (1.4%)
Anticonvulsive medication 4 (5.5%)
Thyroid hormone substitution 11 (15.1%)
Testosterone Substitution 2
Contraceptive pill 1
Clinical features
Visceral obesity 73 (100%)
Abdominal circumference, cm 121 (112; 131)
Purple striae 4 (5.5%)
Moon face 20 (27.4%)
Buffalo hump 27 (37.0%)
Hirsutism 0 (0%)
Easy bruising 0 (0%)
Facial plethora 3 (4.1%)
Akne 2 (2.7%)
Body impedance analysis
Fat mass, % of total body 36 (26; 42)
Muscle mass, % of total body 45 (39; 53)
Fat free mass, % of total body 64 (58; 74)
Body metabolic rate, kcal 1900 (1700; 2190)
Laboratory values
HbA1c (%) 6.5 (5.8; 8.2)
Triglycerides (mmol/L) 1.7 (1.3; 2.5)
Total cholesterol (mmol/L) 4.6 (3.6; 5.3)
LDL-cholesterol (mmol/L) 2.4 (1.7; 3.1)
HDL-cholesterol (mmol/L) 1.1 (0.9; 1.4)
Data are median (IQR) or number (%), unless otherwise stated.
Figure 3. Comparison of serum cortisol, salivary cortisol, and ACTH
levels before and after IL-1 antagonism. Comparisons of baseline
serum cortisol (a), salivary cortisol (b), and ACTH levels (c) with their
equivalent after short-term treatment with anakinra using
a Wilcoxon test.
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to 97.7; P = 0.06). Conversely, a higher percentage of
body fat mass [above median (i.e., 36%)] tended to be
associated with a better treatment response concerning
delta serum cortisol (mean difference, 236.45; 95% CI,
286.80 to 13.89; P = 0.15). We did not find a more
pronounced effect in the subgroup of obese patients
with a psychiatric diagnosis (n = 18) (data not shown).
Side effects/adverse events
No patient withdrew from the study because of drug-
related adverse events. There were no severe and no
unexpected adverse events related to the study drug
anakinra, especially no neutropenia. Main side effects
were mild headache (n = 10) and mild transient injection
site reaction such as pain and local reddening (n = 10).
Three patients developed an exanthema 7 to 10 days after
the first injection of anakinra, with a complete resolution
after a maximum of 3 weeks. All reported adverse events
are listed in Table 3.
Discussion
The main finding of this study is that IL-1 antagonism
leads to an inhibition of the HPA axis decrease in ACTH
and cortisol levels as well as a decrease in systolic blood
pressure and heart rate in obese individuals with at least
one additional feature of the metabolic syndrome. This
suggests a direct interaction between the pathologic ac-
tivation of the innate immune system and stimulation of
the HPA axis in obesity. The inhibition of the HPA axis
upon IL-1 antagonism seems to depend on the extent of
inflammation. It was especially pronounced in patients
with a high inflammatory state (i.e., high IL-6) and was
reduced in patients on statin therapy, which is known to
have anti-inflammatory effects (32).
IL-1 antagonism has been shown to improve glucose
metabolism (33) and is currently under investigation in
the Cardiovascular Risk Reduction Study (Reduction in
Recurrent Major CV Disease Events) (CANTOS) Trial
(NCT01327846) as an anti-inflammatory agent for
secondary prevention of cardiovascular disease and new
onset or progression of type 2 diabetes in patients with
recent myocardial infarction (34). Our data add a pos-
sible mechanism of how IL-1 antagonists may improve
glucose metabolism and thus reduce cardiovascular risk.
Table 2. Effect of Anakinra
Before Anakinra
(n = 73)
Median (IQR)
After Anakinra
(n = 73)
Median (IQR)
Delta Before/After Anakinra
(n = 73) Mean (95% CI) P Value
Hemoglobin, g/L 144 (133; 151) 143 (134; 151) 2.2 (22.0; 6.4) 0.78
Platelets, 3109/L 244 (206; 276) 248 (208; 289) 3.7 (23.8; 11.1) 0.28
Leukocytes, 3109/L 7.1 (6.4; 8.7) 5.7 (4.8; 6.8) 21.3 (22.1; 20.6) ,0.0001
Neutrophil granulocytes,3109/L 4.3 (3.4; 5.3) 2.8 (2.2; 3.7) 20.4 (22.2; 1.4) ,0.0001
C-reactive protein, mg/L 3.4 (1.6; 6.8) 2.6 (1.2; 4.6) 21.9 (23.2; 20.5) ,0.0001
Interleukin-6, pg/mL 3.7 (2.8; 5.8) 1.5 (1.5; 2.4) 22.6 (23.3; 21.9) ,0.0001
Serum cortisol, nmol/L 452 (374; 549) 423 (337; 491) 238.7 (264; 213.4) 0.0019
ACTH, pg/mL 26.4 (19.5; 32.9) 23.7 (19; 33.2) 22.2 (24.2; 20.1) 0.038
Salivary cortisol, nmol/L 19.2 (15; 25.5) 15.5 (11.9, 23.7) 22.8 (24.4; 21.3) 0.0007
Serum cortisol after 1 mg DST 28 (19; 45) 27.5 (20; 45) 10.6 (22.5; 23.7) 0.17
Prolactin, mU/L 224 (142; 297) 213 (153; 306) 10.8 (27.5; 29.1) 0.13
TSH, mIU/La 2.3 (1.5; 3.0) 2.2 (1.6; 2.9) 20.1 (20.2; 0.1) 0.58
Growth hormone, mU/L 1.7 (0.4; 4.8) 1.2 (0.4; 3.7) 21.5 (23.6; 0.6) 0.11
FSH, IU/L 10 (5.4; 32) 10 (4.7; 29.5) 20.4 (21.5; 0.6) 0.62
LH, IU/L 7.8 (4.6; 18.5) 7.1 (4.2; 19.4) 20.4 (22.2; 1.4) 0.12
Albumin, g/L 37 (36; 39) 37 (35; 39) 20.2 (20.7; 0.2) 0.30
Systolic blood pressure, mm Hg 139 (129; 152) 135 (125; 148) 25.2 (28.5; 21.8) 0.0006
Diastolic blood pressure, mm Hg 85 (77; 91) 84 (78; 91) 0.0 (22.0; 1.9) 0.67
Heart rate, beats/min 77 (70; 86) 73 (66; 83) 22.9 (24.7; 21.0) 0.0029
Temperature, C° 36.4 (36.1; 36.8) 36.4 (36.1; 36.7) 0.0 (20.1; 0.1) 0.78
Data are expressed as median (IQR) or number (%) and absolute differences in mean (95% CI) unless stated otherwise. P values were assessed using
the Wilcoxon test.
aOnly 62 patients without thyroid hormone substitution were included.
Table 3. Adverse Events Associated With
Anakinra/Kineret®
N = 73
Mild transient injection site reactions 10 (13.6%)
Exanthema 3 (4.1%)
Mild headache 10 (13.6%)
Nausea 1 (1.4%)
Malaise 3 (4.1%)
Vertigo 5 (6.8%)
Data are number (%).There were no severe and no unexpected adverse
events related to the study drug anakinra, especially no neutropenia.
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Although the magnitude of the effects is mild, this may
still have profound consequence over the years. More-
over, cortisol levels might be a predictor for treatment
response of IL-1 antagonism in diabetic patients.
Notably, we found an important decrease in systolic
blood pressure and heart rate upon IL-1 antagonism.
To our knowledge, this effect of IL-1 antagonism has
not yet been described in humans; however, in rodents,
it has been reported that IL-1 antagonism attenuated
hypertension. The authors postulated a mechanism via
salt retention in the kidney, which is regulated by a
nitric oxide–dependent mechanism (35). Our data
suggest an additional effect via cortisol, which is
known to increase blood pressure. We speculate that
the decrease in heart rate might be explained by the
permissive effect of glucocorticoids on catecholamines
(36). As a result, the decrease of cortisol levels upon
IL-1 antagonism might lead to a decline in the action of
catecholamines and to a negative chronotropic effect.
This finding might point to a causal treatment ap-
proach of IL-1 antagonism for arterial hypertension via
reduction of cortisol levels.
The inhibition of the HPA axis upon IL-1 antagonism
seems to depend on the extent of activation of the innate
immune system. Patientswith high IL-6 levels had a better
treatment response, whereas patients on statins showed a
less pronounced effect. In contrast and unexpectedly,
BMI was a negative predictor for treatment response. It is
possible that the underlying mechanism of treatment is a
dose-dependent effect of the study drug, anakinra, with a
reduced effect in patients with increased body volume.
Increased body fat mass, in contrast, was associated
with a more pronounced treatment effect, suggesting that
the stimulatory effect on theHPA axis via inflammation is
dependent on the amount of adipose tissue in obese
individuals.
That there was not only an effect of IL-1 antagonism
on cortisol levels, but also on ACTH levels, suggests a
central effect on the HPA axis via hypothalamus or the
pituitary gland. An additional direct effect on the adrenal
glands is also possible.
There was no difference in cortisol levels after the 1-mg
dexamethasone suppression test only in comparison with
the 1-mg dexamethasone suppression test plus IL-1 an-
tagonism. It is possible that dexamethasone, with its
strong immunosuppressive properties, overrode the ef-
fect of IL-1 antagonism. In addition, the chronic in-
flammation state of obesity involves different cytokines.
Dexamethasone might have a broader effect on other
cytokines possibly involved in the stimulation of the
HPA axis.
Apart from the HPA axis, we found no effect of IL-1
antagonism on other pituitary hormones. IL-1 has been
reported to have an inhibitory effect on growth hormone,
TSH, LH, and FSH in vitro and in rats (37). However, we
are not aware of data evaluating effects of IL-1 antag-
onism on pituitary hormones in humans. The lack of
effect of IL-1 antagonism on other pituitary hormones
in our trial might be due to the rather short treatment
duration.
Our study has limitations. First, the study was not
conducted as a randomized placebo-controlled, but
rather as a prospective open-label, trial. However, we
investigated robust end points, and the observed anti-
inflammatory effects of anakinra, which correlated with
the decrease in cortisol, are unlikely from “placebo ef-
fects.” Second, patients had only a short treatment ex-
posure of three injections of anakinra. It is possible that
longer treatment duration would have resulted in a more
pronounced treatment effect. In line with this reasoning,
improvement of glucose metabolism upon IL-1 antago-
nism requires several weeks of treatment to reach a
maximal effect (20).
We herein show that IL-1 antagonism in obese patients
reduced the overactivated HPA axis leading to a decrease
in ACTH and cortisol levels as well as a decrease in
systolic blood pressure and heart rate. If our findings are
confirmed in a placebo-controlled, double-blind study,
IL-1 antagonism could be a treatment option to improve
cortisol levels in obesity and thereby prevent metabolic
and cardiovascular complications.
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